Novavax said in a statement that a clinical trial will include 2 665 healthy adults with HIV whose immune responses may differ from those who dont have it. Preliminary findings from the first trial showed people receiving the two doses generated from neutralizing anti-bodies , which can prevent the virus from entering cells , after receiving the second dose of the vaccine.
Along with eveluating immune response in the phase 2b trial in South Africa . The same company will introduce 2nd phase in the US as well. And Australia will follow in the near future.
In Navavax statement Dr Gregory John , president of research and development at Navavax said South Africa's surge in covid 19 cases lends importance on phase 2b clinical trial , with the potential to provide an early indication of efficiency, along with additional safety and immunogenicity data for the vaccine.
South Africa is the fifth most affected country world wide, with more than 583 000 cases and more than 11 600 deaths. Navavax said the trial in SA is made possible in part by a $15 million grant from Bill &Melinda Gates Foundation.
The coalition for Epidemic Preparedness Innovations is providing funds to manufacture doses of the vaccine required for the trial. Last month US government awarded Nanavax a $1.6 billion contract to cover testing and development of a vaccine for the virus in the United States , with a goal of producing 100 million doses by January.
Please share ; like and comment.
Don't Forget To Follow Me For More Current Affairs.
Thank you for reading.
Content created and supplied by: NtobekoTheCreator (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More